Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Ergomed joins Aeterna Zentaris for Phase III cancer trial
May 2013
SHARING OPTIONS:

QUEBEC CITYŚAeterna Zentaris Inc. announced in early April the establishment of a co-development and profit-sharing agreement with Ergomed Clinical Research Ltd. for AEZS-108 in endometrial cancer. Ergomed was chosen to conduct the upcoming multi-center Phase III trial of AEZS-108 in endometrial cancer. Per the agreement, Ergomed will assume 30 percent (up to $10 million) of the clinical and regulatory costs for the Phase III trial, with its return on investment based on a single-digit percentage of any net income that Aeterna Zentaris receives for AEZS-108 in endometrial cancer, up to a predetermined maximum amount. The study will compare AEZS-108 with doxorubicin as a second-line therapy for locally advanced, recurrent or metastatic endometrial cancer. Approximately 500 patients will be enrolled, with the primary efficacy endpoint of improvement in median overall survival.  

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.